Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology (European Journal of Nuclear Medicine and Molecular Imaging (2008) 35, (1581-1588) DOI: 10.1007/s00259-008-0826-x);Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 8, 2008, Pages 1581-1588

  Stauss, J ^a   Franzius, C ^b   Pfluger, T ^c   Juergens, K U ^d   Biassoni, L ^e   Begent, J ^e   Kluge, R ^f   Amthauer, H ^g   Voelker, T ^g   Hojgaard L ^h   Barrington, S ⁱ   Hain, S ^j   Lynch, T ^k   Hahn, K ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Hospital Bremen Mitte   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h Rigshospitalet   (Denmark)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^k ROYAL VICTORIA HOSPITAL   (United Kingdom)

more..

Author keywords

18F FDG PET; Pediatric PET

Indexed keywords

BENZODIAZEPINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER DIAGNOSIS; CHILDHOOD CANCER; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIURESIS; DRUG ACTIVITY; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PUBLICATION; RADIATION DOSE; REVIEW; ARTICLE; CHILD; EUROPE; NEOPLASM; ONCOLOGY; PEDIATRICS; STANDARD;

CHILD; EUROPE; FLUORODEOXYGLUCOSE F18; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PEDIATRICS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 48149105467     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0953-4     Document Type: Erratum

References (45)

1. P Bartenstein S Asenbaum A Catafau C Halldin L Pilowski A Pupi 2002 European Association of Nuclear Medicine. European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG Eur J Nucl Med Mol Imaging 29 BP43 BP48
2. E Bombardieri C Aktolun RP Baum A Bishof-Delaloye J Buscombe JF Chatal 2003 FDG-PET: procedure guidelines for tumour imaging Eur J Nucl Med Mol Imaging 30 BP115 BP124
3. HT Chugani 1998 A critical period of brain development: studies of cerebral glucose utilization with PET Prev Med 27 184 188
4. El Fakhri G, Holdsworth C, Badawi RD, Santos PA, Moore SC, Van den Abbeele AD, Kijewski MF. Impact of acquisition geometry and patient habitus on lewsion detectability in whole body FDG-PET: a channelized hotelling observer study. In: IEEE Nuclear Science Symposium Conference Record. Piscataway, NJ: IEEE, 2002:3:1402-1405.
5. C Franzius KU Juergens J Vormoor 2006 PET/CT with diagnostic CT in the evaluation of childhood sarcoma AJR Am J Roentgenol 186 581
6. C Franzius KU Juergens O Schober 2006 Is PET/CT necessary in paediatric oncology?: For Eur J Nucl Med Mol Imaging 33 960 965
7. C Franzius J Vormoor M Weckesser KU Jürgens O Schober 2006 Optimised PET/CT protocols with diagnostic contrast enhanced multi-slice CT and low-dose CT in paediatric patients: Analysis of more than 350 examinations Eur J Nucl Med Mol Imaging 33 Suppl 2 124
8. M Gelfand S O'Hara L Curtwright 2005 Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients Pediatr Radiol 35 984 990
9. K Hahn T Pfluger 2006 Is PET/CT necessary in paediatric oncology?: Against Eur J Nucl Med Mol Imaging 33 966 968
10. S Holm L Borgwardt A Loft J Graff I Law L Hojgaard 2007 Paediatric doses-a critical appraisal of the EANM paediatric dosage card Eur J Nucl Med Mol Imaging. 34 1713 1718
11. ICRP Publication 80 1998 Radiation dose to patients from radiopharmaceuticals Annals of ICRP 28 3
12. M Lassmann L Biassoni M Monsieurs C Franzius F Jacobs 2007 EANM Dosimetry and Paediatrics Committees. The new EANM paediatric dosage card Eur J Nucl Med Mol Imaging 34 796 798
13. Lassmann M, Biassoni L, Monsieurs M, Franzius C. The new EANM Paediatric Dosage Card. Additional notes with respect to F-18. Eur J Nucl Med Mol Imaging 2008; (in press).
14. O Parysow AM Mollerach V Jager S Racioppi J San Roman VH Gerbaudo 2007 Low-dose oral propranolol could reduce brown adipose tissue F-18 FDG uptake in patients undergoing PET scans Clin Nucl Med 32 351 357
15. V Söderlund SA Larsson H Jacobsson 2007 Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol Eur J Nucl Med Mol Imaging 34 1018 1022
16. VS Warbey PJ Schleyer SF Barrington MJ O'Doherty 2007 The new EANM paediatric dosage card - does it conform to ALARA for PET/CT? Eur J Nucl Med Mol Imaging 34 1881 1882
17. H Amthauer C Furth T Denecke P Hundsdoerfer T Voelker K Seeger 2005 FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up Klin Padiatr 217 327 333
18. SF Barrington J Begent T Lynch P Schleyer L Biassoni W Ramsden 2008 Guidelines for the use of PET-CT in children Nucl Med Commun 29 5 418 424
19. L Borgwardt HJ Larsen K Pedersen L Hojgaard 2003 Practical use and implementation of PET in children in a hospital PET centre Eur J Nucl Med Mol Imaging 30 1389 1397
20. 18F -FDG PET: age dependency and frequency after chemotherapy J Nucl Med 42 591 595
21. FH Fahey MR Palmer KJ Strauss 2007 Dosimetry and adequacy of CT-based attenuation correction for pediatric PET: phantom study Radiology 243 96 104
22. C Franzius J Sciuk C Brinkschmidt H Jurgens O Schrober 2000 Evaluation of chemotherapy response in primary bone tumours with F-18 FDG positron emission tomography compared with histologically assessed tumour necrosis Clin Nucl Med 25 874 871
23. C Franzius J Sciuk HE Daldrup-Link H Jurgens O Schober 2000 FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy Eur J Nucl Med 27 1305 1311
24. C Franzius HE Daldrup-Link J Sciuk EJ Rummeny S Bielack H Jurgens 2001 FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT Ann Oncol 12 479 486
25. C Franzius HE Daldrup-Link A Wagner-Bohn J Sciuk WL Heindel H Jürgens 2002 FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional staging Ann Oncol 13 157 160
26. C Franzius O Schober 2003 Assessment of therapy response by FDG PET in pediatric patients Q J Nucl Med 47 41 45
27. A Gutzeit JF Debatin G Antoch 2004 Tumor staging with PET/CT. Detection of a second tumor Rofo 176 122 124
28. K Hahn T Pfluger 2004 Has PET become an important clinical tool in paediatric imaging? Eur J Nucl Med Mol Imaging 31 615 621
29. DS Hawkins JG Rajendran EU Conrad 3rd JD Bruckner JF Eary 2002 Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d- glucose positron emission tomography Cancer 94 3277 3284
30. S Herrmann D Wormanns M Pixberg A Hunold WL Heindel H Jurgens 2005 Staging in childhood lymphoma: differences between FDG-PET and CT Nuklearmedizin 44 1 7
31. F Jacobs H Thierens A Piepsz K Bacher C Van de Wiele H Ham RA Dierckx European Association of Nuclear Medicine 2005 Optimised tracer-dependent dosage cards to obtain weight-independent effective doses Eur J Nucl Med Mol Imaging 32 581 588
32. KU Juergens M Weckesser L Stegger C Franzius M Beetz O Schober 2006 Tumor staging using whole-body high-resolution 16-channel PET-CT: does additional low-dose chest CT in inspiration improve the detection of solitary pulmonary nodules? Eur Radiol 16 1131 1137
33. S Kaste S Howard E McCarville 2005 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's Pediatr Radiol. 35 141 154
34. S Kaste 2004 Issues specific to implementing PET-CT for pediatric oncology: what have we learned along the way? Pediatr Radiol 34 205 213
35. 18F-Fluorodeoxy-d-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence-consequences for the GPOH-HD 2003 protocol Onkologie 26 489 493
36. BH Kushner HW Yeung SM Larson K Kramer NK Cheung 2001 Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients J Clin Oncol 19 3397 3405
37. JD Lucas MJ O'Doherty JCH Wong 1998 Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas J Bone Joint Surg (Br) 80 441 447
38. JD Lucas MJ O'Doherty BF Cronin PK Marsden MA Lodge PH McKee 1999 Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography Br J Surg 86 550 556
39. MB McCarville R Christie NC Daw SL Spunt SC Kaste 2005 PET/CT in evaluation of childhood sarcomas Am J Roentgenol 184 1293 1304
40. 18F]FDG in childhood lymphoma: clinical utility and impact on management Eur J Nucl Med Mol Imaging 29 1155 1165
41. SM O'Hara LF Donnelly RE Coleman 1999 Pediatric body applications of FDG PET AJR Am J Roentgenol 172 1019 1024
42. BL Shulkin 1997 PET applications in pediatrics Q J Nucl Med 41 281 291
43. BL Shulkin RJ Hutchinson VP Castle GA Yanik B Shapiro JC Sisson 1996 Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy- d-glucose compared with metaiodobenzylguanidine scintigraphy Radiology 199 743 750
44. MG Stabin MJ Gelfand 1998 Dosimetry of pediatric nuclear medicine procedures Q J Nucl Med 42 93 112
45. E Wegner S Barrington J Kingston 2005 The impact of PET scanning on management of paediatric oncology patients Eur J Nucl Med Mol Imaging 32 23 30